🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

LITT for Ultra-early GBM Recurrence

RecruitingNAAges 18 Years - anyAllInsel Gruppe AG, University Hospital Bern
NCT07616986 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Glioblastoma (GBM) remains aggressive despite standard therapy (surgery (CRET) + RT/CT). Over 40% of patients develop recurrence between surgery and pre-RT MRI, with median overall survival (OS) of 13.3m and 24.4m for patients with and without recurrence in pre-RT MRI, respectively. Reoperation is avoided as it delays adjuvant therapy. LITT offers a minimally invasive alternative that may: * Treat recurrence without delaying RT/CT * Potentially sensitize tumors to subsequent therapy This study tests if LITT can be practically integrated within the critical 1-week window between pre-RT MRI and radiotherapy initiation, maintaining the adjuvant schedule.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Histologically confirmed glioblastoma, IDH-wildtype, regardless of MGMT status * ≥18 years of age * CRET * Karnofsky Performance Status (KPS) ≥70 * No contra-indication for radio-chemotherapy * Scheduled for adjuvant radio-chemotherapy at University Hospital of Bern * Able to provide informed consent * No contra-indication for LITT * No pregnancy or active breast-feeding * No known coagulopathy independent of medication * No dissemination or multifocal disease * Patients lacking capacity to consent or considered vulnerable (e.g., minors, those under legal protection) are not included. Exclusion Criteria:
💊

What it tests

  • LITT
📍

Where

1 site
Dep. of Neurosurgery, Bern University Hospital
Bern, Switzerland
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy